EMA Authorised: Locametz (gozetotide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Locametz (gozetotide) for radionuclide imaging, with Novartis Europharm Limited as the marketing authorisation holder; decision dated 31 March 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LOCAMETZ (kit for the preparation of gallium-68 gozetotide)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging. MAH: Novartis Europharm Limited. Decision date: 31/03/2025